Market Place
Sourcing Support
Dyne Therapeutics to Present at Upcoming Investor Conferences
07 Nov 2024 //
GLOBENEWSWIRE
Dyne Presents FORCE Platform Data At World Muscle Society
09 Oct 2024 //
GLOBENEWSWIRE
Dyne To Present At Chardan Genetic Medicines Conference
23 Sep 2024 //
GLOBENEWSWIRE
Three execs resign as Dyne posts mixed data for DMD candidate
04 Sep 2024 //
FIERCE BIOTECH
Dyne Therapeutics Announces Key Leadership Appointments
03 Sep 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Morgan Stanley Global Healthcare Conference
29 Aug 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Q2 2024 Results And Recent Business Highlights
12 Aug 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Presents FORCE™ Platform Data for Pompe Disease Therapy
24 Jun 2024 //
GLOBENEWSWIRE
Dyne Presents Preclinical FSHD Data At FSHD Society Congress
13 Jun 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Dyne Therapeutics: Public Offering, Additional Shares Option Exercised
28 May 2024 //
GLOBENEWSWIRE
Dyne`s $305M offering; Nanobiotix delays Ph2 readout
22 May 2024 //
ENDPTS
Dyne Announces $325.5M Public Offering Of Common Stock
21 May 2024 //
GLOBENEWSWIRE
Dyne shares jump on trial data for muscle disease drugs
21 May 2024 //
BIOPHARMADIVE
Dyne Announces Positive ACHIEVE, DELIVER Biomarker, Functional Data
20 May 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
20 May 2024 //
GLOBENEWSWIRE
Dyne To Host Investor Event On ACHIEVE, DELIVER Trial Data
19 May 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Q1 2024 Results, Business Highlights
02 May 2024 //
GLOBENEWSWIRE
Dyne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 Mar 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
27 Mar 2024 //
PRESS RELEASE
Dyne Therapeutics Announces CEO Transition
25 Mar 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
13 Mar 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Dyne Announces Presentations on Initial Data From ACHIEVE Trial in DM1 Patients
14 Feb 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at February Investor Conferences
01 Feb 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Closing of Public Offering of Common Stock
11 Jan 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
05 Jan 2024 //
GLOBENEWSWIRE
Dyne Announces Pricing of $300 Million Public Offering of Common Stock
04 Jan 2024 //
PRESS RELEASE
Dyne Announces Positive Clinical Data from ACHIEVE Trial in DM1 Patients
03 Jan 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
03 Jan 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET
02 Jan 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at November Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Third Quarter 2023 Financial Results
30 Oct 2023 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at October Investor Conferences
28 Sep 2023 //
PRESS RELEASE
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101
20 Sep 2023 //
GLOBENEWSWIRE
Dyne to Present at Morgan Stanley 21st Annual Global Healthcare Conference
05 Sep 2023 //
GLOBENEWSWIRE
Dyne Reports Second Quarter 2023 Financial Results and Business Highlights
03 Aug 2023 //
GLOBENEWSWIRE
Insiders Could Have Profited By Holding onto Dyne Shares Despite 16% Drop
17 Jun 2023 //
SIMPLY WALL
Dyne Therapeutics to Present at Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Receives EMA Orphan Drug Designation for DYNE-101
25 May 2023 //
PRESS RELEASE
Dyne Therapeutics Receive EMA Orphan Drug Designation for DYNE-101
25 May 2023 //
GLOBENEWSWIRE
Dyne Preclinical Data Demonstrating FORCE Platform at ASGCT
17 May 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
03 May 2023 //
GLOBENEWSWIRE
Dyne to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating
02 May 2023 //
GLOBENEWSWIRE
Dyne Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251
23 Mar 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs
20 Mar 2023 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Upcoming Investor Conferences
07 Mar 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251
31 Oct 2022 //
GLOBENEWSWIRE
Dyne Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs
11 Oct 2022 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Chardan’s 6th Annual Medicines Conference
27 Sep 2022 //
GLOBENEWSWIRE
Dyne Announces First Patient Dosed in Ph1/2 DELIVER Clinical Trial of DYNE-251
06 Sep 2022 //
GLOBENEWSWIRE
Dyne Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101
06 Sep 2022 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare
06 Sep 2022 //
GLOBENEWSWIRE
Dyne Therapeutics Appoints Francesco Bibbiani as SVP, Head of Development
29 Aug 2022 //
GLOBENEWSWIRE
Dyne Announces “Breakthrough Article” Publication
10 Aug 2022 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Clearance of CTA for DYNE-101 for MD Type 1
12 Jul 2022 //
GLOBENEWSWIRE
